X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-03 | XERS | Xeris Biopharma Holdings, Inc. | Persky Marla | Dir | S - Sale+OE | $5.90 | -15,500 | 157,063 | -9% | -$91,433 | |||||
| D | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | Halkuff Dawn | Dir | S - Sale+OE | $6.09 | -20,000 | 124,603 | -14% | -$121,886 | |||||
| D | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | Bormann-Kennedy Barbara-Jean Anne | Dir | S - Sale+OE | $6.09 | -16,000 | 150,693 | -10% | -$97,507 | |||||
| D | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | Johnson John | Dir | S - Sale+OE | $6.09 | -15,000 | 707,276 | -2% | -$91,422 | |||||
2026-06-04 | PCRX | Pacira Biosciences, Inc. | Williams Kristen | Chief Administrative Officer | S - Sale | $22.27 | -10,259 | 167,062 | -6% | -$228,468 | ||||||
| M | 2026-06-03 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $4.37 | -8,285 | 373,224 | -2% | -$36,209 | |||||
| D | 2026-06-03 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale+OE | $30.01 | -2,645 | 20,439 | -11% | -$79,376 | |||||
| D | 2026-06-05 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $2.93 | -14,584 | 62,586 | -19% | -$42,737 | |||||
| M | 2026-06-04 | EQ | Equillium, Inc. | Connelly Stephen | Pres, CSO | S - Sale | $3.13 | -230,975 | 762,025 | -23% | -$723,830 | |||||
| D | 2026-06-04 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $546.28 | -10,000 | 18,876 | -35% | -$5,462,824 | |||||
| D | 2026-06-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $546.33 | -9,500 | 668,728 | -1% | -$5,190,128 | |||||
2026-06-03 | ALDX | Aldeyra Therapeutics, Inc. | Brady Todd C | Pres, CEO | P - Purchase | $1.67 | +250,000 | 1,721,298 | +17% | +$418,450 | ||||||
2026-06-03 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $102.27 | -2,370 | 98,603 | -2% | -$242,380 | ||||||
2026-06-04 | KROS | Keros Therapeutics, Inc. | Seth Alpna | Dir | S - Sale | $10.72 | -2,625 | 9,767 | -21% | -$28,140 | ||||||
2026-06-03 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale | $102.27 | -2,404 | 69,082 | -3% | -$245,857 | ||||||
2026-06-03 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $102.27 | -2,159 | 39,454 | -5% | -$220,801 | ||||||
2026-06-03 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale | $102.27 | -7,605 | 499,356 | -2% | -$777,763 | ||||||
| M | 2026-06-03 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $102.90 | -4,424 | 60,486 | -7% | -$455,248 | |||||
2026-06-03 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $17.48 | +2,500 | 22,500 | +13% | +$43,700 | ||||||
2026-06-03 | LFVN | Lifevantage Corp | Beindorff Michael A | Dir | S - Sale | $8.55 | -10,000 | 74,821 | -12% | -$85,459 | ||||||
2026-06-03 | OCUL | Ocular Therapeutix, Inc | Waheed Nadia | Chief Medical Officer | S - Sale | $8.27 | -14,828 | 300,079 | -5% | -$122,628 | ||||||
2026-06-04 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $9.31 | +50,000 | 1,068,000 | +5% | +$465,295 | ||||||
2026-06-03 | GNLX | Genelux Corp | Smalling Ralph | Head of Regulatory | S - Sale | $2.93 | -192 | 67,611 | 0% | -$563 | ||||||
2026-06-02 | JANX | Janux Therapeutics, Inc. | Doyle Janeen Noel | Chief Corp., Bus. Dev. Ofcr | S - Sale | $14.03 | -4,059 | 75,941 | -5% | -$56,944 | ||||||
2026-06-04 | SMMT | Summit Therapeutics Inc. | Duggan Robert W | Co-CEO, 10% | P - Purchase | $14.60 | +100,000 | 606,205,809 | 0% | +$1,460,000 | ||||||
2026-06-04 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | $14.60 | +100,000 | 606,205,809 | 0% | +$1,460,000 | ||||||
| D | 2026-06-04 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $547.07 | -8,300 | 45,172 | -16% | -$4,540,642 | |||||
2026-06-04 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $43.05 | -2,034 | 229,524 | -1% | -$87,564 | ||||||
| D | 2026-06-02 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $70.60 | -20,000 | 3,985 | -83% | -$1,412,000 | |||||
2026-06-04 | SMMT | Summit Therapeutics Inc. | Soni Manmeet Singh | COO, CFO | P - Purchase | $14.45 | +50,000 | 3,123,603 | +2% | +$722,250 | ||||||
| D | 2026-06-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.61 | -9,500 | 668,728 | -1% | -$5,202,271 | |||||
| D | 2026-06-03 | TEVA | Teva Pharmaceutical Industries Ltd | Shields Matthew | EVP, Global Operations | S - Sale+OE | $32.87 | -16,195 | 9,989 | -62% | -$532,330 | |||||
| D | 2026-06-03 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | S - Sale+OE | $75.00 | -8,333 | 0 | -100% | -$624,975 | |||||
2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $70.43 | -15,000 | 597,540 | -2% | -$1,056,486 | ||||||
| D | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $71.06 | -7,500 | 97,994 | -7% | -$532,937 | |||||
| D | 2026-06-02 | EVMN | Evommune, Inc. | Cohen David E | Dir | S - Sale+OE | $20.33 | -6,056 | 17,609 | -26% | -$123,094 | |||||
| D | 2026-06-01 | EVMN | Evommune, Inc. | Patel Jeegar Pravinkumar | Chief Scientific Officer | S - Sale+OE | $22.74 | -16,687 | 46,403 | -26% | -$379,462 | |||||
2026-06-01 | EVMN | Evommune, Inc. | Pena Luis C. | Pres, CEO | S - Sale | $22.74 | -16,787 | 637,896 | -3% | -$381,736 | ||||||
| D | 2026-06-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $70.21 | -25,000 | 119,472 | -17% | -$1,755,183 | |||||
| D | 2026-06-01 | CORT | Corcept Therapeutics Inc | Mokari Atabak | CFO | S - Sale+OE | $70.00 | -40,000 | 16,130 | -71% | -$2,800,004 | |||||
| D | 2026-06-01 | SEPN | Septerna, Inc. | Shaikhly Samira | Chief People Officer | S - Sale+OE | $28.93 | -5,935 | 793 | -88% | -$171,682 | |||||
2026-06-01 | NATR | Natures Sunshine Products Inc | Norman Daniel C | EVP, Pres, Asia | S - Sale | $20.64 | -9,713 | 47,276 | -17% | -$200,476 | ||||||
| M | 2026-06-01 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.46 | -139,803 | 482,776 | -22% | -$63,628 | |||||
| D | 2026-06-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $22.87 | -27,000 | 115,743 | -19% | -$617,571 | |||||
| M | 2026-06-02 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Chief Business Officer | P - Purchase | $7.50 | +13,500 | 75,300 | +22% | +$101,219 | |||||
| D | 2026-06-01 | IONS | Ionis Pharmaceuticals Inc | Berthelsen Spencer R | Dir | S - Sale+OE | $75.67 | -8,000 | 156,083 | -5% | -$605,360 | |||||
2026-06-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $30.58 | -1,795 | 34,826 | -5% | -$54,891 | ||||||
2026-06-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $235.12 | -6,000 | 372,682 | -2% | -$1,410,720 | ||||||
| D | 2026-06-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $538.39 | -9,500 | 668,728 | -1% | -$5,114,742 | |||||
2026-06-01 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $60.87 | -276 | 146,743 | 0% | -$16,800 | ||||||
| M | 2026-06-01 | LQDA | Liquidia Corp | Kirsch Arthur S | Dir | S - Sale | $57.71 | -30,000 | 40,755 | -42% | -$1,731,300 | |||||
| D | 2026-06-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $98.69 | -11,430 | 85,533 | -12% | -$1,128,080 | |||||
| D | 2026-06-01 | ALNY | Alnylam Pharmaceuticals, Inc. | Pyott David E I | Dir | S - Sale+OE | $299.18 | -3,830 | 29,482 | -11% | -$1,145,853 | |||||
2026-06-01 | ONC | Beone Medicines Ltd. | Yi Qingqing | Dir | S - Sale | $279.13 | -235 | 24,271 | -1% | -$65,596 | ||||||
2026-06-01 | VRTX | Vertex Pharmaceuticals Inc / Ma | Liu Joy | EVP, GC | S - Sale | $439.91 | -828 | 19,959 | -4% | -$364,245 | ||||||
2026-06-02 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $9.43 | +50,000 | 1,018,000 | +5% | +$471,300 | ||||||
2026-06-01 | SPRC | Scisparc Ltd. | Shrem Itschak | Dir | S - Sale | $10.00 | -462 | 10,596 | -4% | -$4,620 | ||||||
| DM | 2026-05-29 | AUPH | Aurinia Pharmaceuticals Inc. | Tang Kevin | CEO, 10% | P - Purchase | $15.29 | +814,606 | 13,044,106 | +7% | +$12,455,227 | |||||
2026-06-01 | GNLX | Genelux Corp | Thomas John | Dir | S - Sale | $2.98 | -10,000 | 472,784 | -2% | -$29,801 | ||||||
| M | 2026-05-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $4.72 | -652 | 381,509 | 0% | -$3,075 | |||||
| D | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $95.84 | -30,000 | 381,809 | -7% | -$2,875,103 | |||||
| D | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $100.00 | -3,977 | 0 | -100% | -$397,700 | |||||
| D | 2026-06-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $16.60 | -8,148 | 13,579 | -38% | -$135,253 | |||||
| D | 2026-06-01 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $90.62 | -26,530 | 4,000 | -87% | -$2,404,077 | |||||
| M | 2026-05-29 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $229.20 | -17,537 | 433,459 | -4% | -$4,019,470 | |||||
2026-05-29 | PAHC | Phibro Animal Health Corp | Corcoran E Thomas | Dir | P - Purchase | $31.77 | +10,000 | 41,459 | +32% | +$317,700 | ||||||
| D | 2026-06-01 | NBP | Novabridge Biosciences | Xu Cong Claire | SVP, Clinical Development | S - Sale+OE | $3.94 | -3,494 | 290,154 | -1% | -$13,766 | |||||
| D | 2026-06-01 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale+OE | $227.06 | -5,000 | 41,382 | -11% | -$1,135,316 | |||||
| M | 2026-06-01 | HYPD | Hyperion Defi, Inc. | Jung Hyunsu | See Remarks | P - Purchase | $3.70 | +8,000 | 1,385,676 | +1% | +$29,580 | |||||
2026-06-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $6.06 | -16,667 | 1,176,506 | -1% | -$100,982 | ||||||
| D | 2026-06-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.91 | -9,500 | 668,728 | -1% | -$5,205,105 | |||||
| D | 2026-06-01 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $547.87 | -10,000 | 18,876 | -35% | -$5,478,663 | |||||
| A | 2026-05-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $575.97 | -1,500 | 43,153 | -3% | -$863,947 | |||||
2026-05-29 | ANTX | An2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | S - Sale | $4.43 | -265 | 66,583 | 0% | -$1,174 | ||||||
2026-05-29 | CNTB | Connect Biopharma Holdings Ltd | Huang James | Dir | P - Purchase | $2.48 | +150,000 | 13,310,000 | +1% | +$371,610 | ||||||
2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $18.99 | -1,177 | 139,252 | -1% | -$22,351 | ||||||
2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale | $18.99 | -6,847 | 484,843 | -1% | -$130,025 | ||||||
2026-06-02 | ASND | Ascendis Pharma A/S | Smith Scott Thomas | EVP, CFO | P - Purchase | $219.00 | +100 | 4,367 | +2% | +$21,900 | ||||||
2026-06-01 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $69.74 | -12,837 | 2,865,489 | 0% | -$895,252 | ||||||
2026-05-29 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -1,974 | 22,760 | -8% | -$888,300 | ||||||
2026-06-01 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $1.39 | +72,700 | 1,186,221 | +7% | +$100,886 | ||||||
2026-06-01 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.34 | +75,000 | 1,532,918 | +5% | +$100,200 | ||||||
2026-06-01 | MAIA | Maia Biotechnology, Inc. | Gryaznov Sergei | Chief Scientific Officer | P - Purchase | $1.35 | +2,000 | 46,511 | +4% | +$2,690 | ||||||
2026-05-29 | KRRO | Korro Bio, Inc. | Aiyar Ram | Pres, CEO | S - Sale | $12.98 | -15,152 | 79,461 | -16% | -$196,673 | ||||||
2026-05-28 | QTTB | Q32 Bio Inc. | Xu Diyong | Dir, 10% | P - Purchase | $8.00 | +1,875,000 | 625,000 | -150% | +$15,000,000 | ||||||
2026-05-28 | QTTB | Q32 Bio Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $8.00 | +1,875,000 | 625,000 | -150% | +$15,000,000 | ||||||
| D | 2026-05-28 | EVMN | Evommune, Inc. | Moss Gregory S. | Chief Business, Legal Officer | S - Sale+OE | $22.83 | -14,223 | 64,010 | -18% | -$324,711 | |||||
| D | 2026-05-28 | EVMN | Evommune, Inc. | Carver Kyle | CFO | S - Sale+OE | $22.84 | -18,175 | 59,335 | -23% | -$415,117 | |||||
2026-06-01 | MDGL | Madrigal Pharmaceuticals, Inc. | Soergel David | Chief Medical Officer | S - Sale | $495.74 | -1,042 | 10,033 | -9% | -$516,561 | ||||||
| D | 2026-06-01 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $41.67 | -9,000 | 77,389 | -10% | -$375,044 | |||||
2026-06-01 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale | $25.77 | -2,562 | 39,581 | -6% | -$66,024 | ||||||
2026-06-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $23.77 | -4,653 | 105,689 | -4% | -$110,602 | ||||||
2026-06-01 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale | $76.09 | -2,933 | 10,283 | -22% | -$223,172 | ||||||
| D | 2026-06-01 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $74.08 | -15,000 | 58,555 | -20% | -$1,111,200 | |||||
2026-06-01 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $74.08 | -5,000 | 15,784 | -24% | -$370,400 | ||||||
| D | 2026-05-29 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $99.64 | -9,000 | 7,825 | -53% | -$896,760 | |||||
2026-06-01 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $13.16 | -4,170 | 149,482 | -3% | -$54,862 | ||||||
2026-05-28 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $13.95 | -2,860 | 194,655 | -1% | -$39,897 | ||||||
2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | S - Sale | $20.02 | -25,000 | 130,142 | -16% | -$500,543 | ||||||
2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | See remarks below, 10% | S - Sale | $20.02 | -25,000 | 130,142 | -16% | -$500,543 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |